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Summary
The peroxisome-biogenesis disorders (PBDs) are a set of
often lethal genetic diseases characterized by mental re-
tardation and defective peroxisomal matrix protein im-
port. Mutations in PEX12 are known to underlie the
disease in two patients from complementation group 3
of the PBDs. Here we show that all patients from this
group carry mutations on both alleles of PEX12. A com-
parison between PEX12 genotypes and the clinical and
cellular phenotypes of the corresponding PBD patients
suggests a relatively straightforward relationship be-
tween genotype and phenotype in this group of the
PBDs, such that the loss of PEX12 function leads to
more-severe cellular and clinical phenotypes. However,
one patient who presented relatively mild clinical and
cellular phenotypes was a compound heterozygote for
two seemingly severe mutations on each PEX12 allele.
PEX12 mRNA present in the patient’s cells was derived
from only one allele, the one that carried a 2-bp deletion
early in the PEX12 coding region, c.26,27D. The de-
duced protein product of this mRNA would contain only
the first eight amino acids of the protein, and yet this
mutant PEX12 cDNA displayed significant PEX12 ac-
tivity in a functional complementation assay. Surpris-
ingly, the PEX12/c.26,27D cDNA directed the synthesis
of a 29-kD PEX12 protein in vitro, a result that is con-
sistent with translation initiation at a downstream AUG
codon. Transfection studies confirmed the expression of
similarly sized PEX12 proteins from the PEX12/
c.26,27D allele. Thus, it appears that translation initi-
ation at internal AUG codons may modulate disease
phenotypes and should be considered whenever unex-
pectedly mild phenotypes result from severe mutations
early in the coding region.
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Introduction
Two distinct clinical spectra have been recognized within
the peroxisome-biogenesis disorders (PBDs). One is
composed of Zellweger syndrome (ZS), neonatal adre-
noleukodystrophy (NALD), and infantile Refsum dis-
ease (IRD) and is referred to as “the Zellweger spec-
trum.” Within the Zellweger spectrum of disease, ZS is
the most severe and is typified by neurological, hepatic,
and renal abnormalities, pronounced mental retarda-
tion, and death in early infancy. NALD patients display
a generally less severe and more restricted set of phe-
notypes, and IRD phenotypes are even milder. There are
at least nine complementation groups (CGs) of Zell-
weger-spectrum patients (Shimozawa et al. 1993), but
there is no relationship between disease phenotype and
CG. The other spectrum of phenotypes is typified by
classical rhizomelic chondrodysplasia punctata (cRCDP)
(Lazarow and Moser 1995) but also includes patients
with milder phenotypic variations (Moser et al. 1995).
In contrast to Zellweger-spectrum patients, cRCDP pa-
tients lie within a single CG and display proximal short-
ening of the long bones of the limbs and extensive punc-
tate calcifications in addition to the severe neurological
deficits and mental retardation observed in all PBD pa-
tients (Lazarow and Moser 1995).
All PBD patients display defects in multiple peroxi-
somal metabolic processes, and these result from an in-
ability to import peroxisomal matrix proteins. Newly
synthesized peroxisomal proteins are imported into per-
oxisomes posttranslationally and carry either of two per-
oxisomal targeting signals (PTSs) that are sufficient to
direct them to and into the peroxisome: the PTS1 or the
PTS2 (Subramani 1993). The fact that all Zellweger-
spectrum patients exhibit a defect in PTS1-protein im-
port and that all cRCDP patients display a selective de-
fect in PTS2-protein import demonstrates that these two
clinical spectra are heavily influenced by the specificity
of these import pathways (Slawecki et al. 1995). The
PTS1, a C-terminal tripeptide of the sequence ser-lys-
leu-COOH (SKL) or a variant thereof, targets the majority
of proteins to peroxisomes (Gould et al. 1989). This
includes the enzymes acyl-CoA oxidase and D-specific
hydratase/dehydrogenase, the enzymes defective in two
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diseases with clinical symptoms similar to ZS, pseudo-
NALD (Poll-The et al. 1988) and pseudo-ZS (Suzuki et
al. 1997), respectively. In contrast to the PTS1, the PTS2
(Swinkels et al. 1991) is found at or near the N-terminus
of proteins, consists of the sequence RLX5HL, and tar-
gets only a few proteins to peroxisomes. In fact, only
three PTS2-containing proteins are known in humans:
thiolase (Swinkels et al. 1991), phytanoyl-CoA a-hy-
droxylase (PAHX) (Jansen et al. 1997; Mihalik et al.
1997), and alkyl-dihydroxyacetonephosphate synthase
(de Vet et al. 1997). Integral peroxisomal membrane
proteins use neither a PTS1 nor a PTS2 but, rather, em-
ploy a distinct class of PTS (Dyer et al. 1996).
Peroxisomal protein import requires a diverse set of
peroxisome-assembly factors, referred to as “peroxins.”
Studies on yeast- and mammalian-cell mutants defective
in peroxisomal protein import have led to the identifi-
cation of various peroxins involved in recognition, tar-
geting, and translocation of proteins into peroxisomes.
These peroxins include the PTS1 receptor PEX5, the
PTS2 receptor PEX7, and 16 other peroxisome-associ-
ated proteins required for import of both PTS1 and PTS2
proteins (van der Klei and Veenhuis 1997). To date, 14
human PEX genes have been identified, including the
genes mutated in PBD patients representing CG1 (PEX1;
Portsteffen et al. 1997; Reuber et al. 1997), CG2 (PEX5;
Dodt et al. 1995), CG3 (PEX12; Chang et al. 1997;
Okumoto and Fujiki 1997), CG4 (PEX6; Fukuda et al.
1996; Yahraus et al. 1996), CG7 (PEX10; Warren et al.
1998), CG10 (PEX2; Shimozawa et al. 1992), and
CG11 (PEX7; Braverman et al. 1997; Motley et al.
1997; Purdue et al. 1997). During our initial character-
ization of human PEX12, we identified inactivating mu-
tations on both alleles of PEX12 in two unrelated ZS
patients from CG3 (Chang et al. 1997). In the present
study, we identified the mutations in all five remaining
CG3 patients and characterized the cellular phenotypes
of all seven CG3 patients. Our results provide insights
into PEX12 function, phenotype-genotype relationships
in the PBDs, and the possible modification of disease
phenotypes by translation initiation at internal ATG
codons.
Material and Methods
Cell Lines and Strains
Human skin fibroblast-cell lines from unaffected in-
dividuals were obtained from the Coriell Cell Repository
(Camden, NJ). Skin fibroblasts from PBD patients were
obtained from Ann and Hugo Moser (The Kennedy
Krieger Institute, Baltimore). All fibroblasts were cul-
tured in complete medium (Dulbecco’s modified Eagle’s
medium-high glucose [Dulbecco’s minimal essential me-
dium] supplemented with 10% fetal bovine serum and
penicillin/streptomycin). Transformed derivatives of hu-
man skin fibroblast cells were generated by transfection
with the plasmid pRSV-SV40T, followed by selection for
transformed foci (Dodt et al. 1995). All PBD cell lines
are referred to by patient number. All bacterial manip-
ulations were performed with the Escherichia coli strain
DH10B (Grant et al. 1990).
Northern Blot Analysis and Mutation Detection
RNA was isolated from cultured skin fibroblasts by
use of PUREscript reagents and protocols (Gentra Sys-
tems). For northern analysis, 20 mg of total RNA from
each cell line was separated by denaturing agarose-gel
electrophoresis, transferred to GeneScreen filters (NEN
Life Sciences), and hybridized first with a radiolabeled
PEX12 cDNA probe (including the entire open reading
frame [ORF]) and subsequently with a radiolabeled b-
actin cDNA probe. Levels of each mRNA were inferred
from autoradiography of x-ray film and by phosphori-
mage analysis by use of a Fuji MacBAS phosphorimager.
The PEX12 sequence was examined at the level of
genomic DNA. Genomic DNAs were extracted from
skin fibroblasts by use of the TurboGen kit (Invitogen).
One hundred nanograms of each sample was used as
the template for amplification of a 2.3-kb fragment of
the PEX12 gene by use of the oligonucleotides Chang-
21 (5′-CAAGGTACCAAGTGAAAGCCAGTACACG-
CAG-3′) at the 5′ end and Chang-20 (5′-CCAG-
GATCCGTGAGGATAAGACATGATTCCC-3′) at the 3′
end. In all cases, the PCR products were sequenced di-
rectly. All mutations were also examined by allele-spe-
cific oligonucleotide (ASO) hybridization (Michaud et
al. 1992). In brief, the 2.3-kb PEX12-gene fragment was
amplified from each patient, transferred to GeneScreen
filters, and hybridized with end-labeled oligonucleotides
(14 nucleotides long) corresponding to the wild-type and
mutant gene sequences. For ASO hybridization analysis,
the oligonucleotides 5′-CTAGATCTTCTGCT-3′ and 5′-
TGCTAGATCTGCTC-3′ were used to discriminate be-
tween the wild-type and mutant sequence of PBD095,
the oligonucleotides 5′-GCTTAAAGAGAATT-3′ and 5′-
CGGCTTAGAATTGT-3′ were used to discriminate be-
tween the wild-type and mutant sequence of PBD096,
and the oligonucleotides 5′-ACTTCACAGCTGCT-3′
and 5′-CACTTCAGCTGCTT-3′ were used to discrimi-
nate between the wild-type and mutant sequence of the
PBD099 c.26,27D allele.
Mutation analysis was also performed at the cDNA
level. First-strand PEX12 cDNA was synthesized by use
of Superscript RT (Life Technologies), 10 mM PEX12-
specific primer (5′-GTCTTGCTACCACCTCACTGTT-
CAC-3′, located in the 3′ UTR), and 5 mg of total RNA
in a volume of 25 ml. A PEX12 cDNA fragment spanning
the entire ORF but lacking most of the 5′ UTR was
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amplified from 2.5 ml of first-strand cDNA by use of the
oligonucleotides Chang-21 at the 5′ end and Chang-20
at the 3′ end. A PEX12 cDNA fragment spanning the
entire ORF as well as the 5′ UTR was amplified from
2.5 ml of first-strand cDNA by use of the oligonucleotides
Chang-120 at the 5′ end and Chang-20 at the 3′ end.
PCR products were gel purified and sequenced directly.
Plasmids and 5′ Rapid Amplification of cDNA Ends
(RACE)
We have already described plasmids designed to
express the PEX12 cDNA (pcDNA3-PEX12), the
PEX12myc cDNA (pcDNA3-PEX12myc) (Chang et al.
1997), and the PAHXmyc cDNA (Mihalik et al. 1997).
The plasmid designed to express the PEX12 gene,
pCC037, was created by amplifying the PEX12 gene
from genomic DNA of an unaffected individual by use
of the oligonucleotides Chang-21 and Chang-20, fol-
lowed by subcloning the resulting 2.3-kb fragment be-
tween the Asp718 and BamHI sites of pcDNA3. Plas-
mids containing all PEX12 alleles from all seven CG3
patients were created in an analogous manner. Recom-
binant techniques were used to remove PCR-generated
mutations from subclones of each allele, ensuring that
the PEX12 gene accurately reflected the sequence of each
allele. The PEX12/c.26,27D cDNA was generated, by
reverse transcription–PCR (RT-PCR), from PBD099
RNA as described above, followed by cleavage of the
cDNA fragment with Asp718 and BamHI and insertion
of this fragment between the Asp718 and BamHI sites
of pcDNA3, creating pcDNA3-PEX12/c.26,27D (the
only cDNA detected in this patient is derived from this
allele). Sequence analysis confirmed that the deletion of
nucleotides 26 and 27 of the ORF were the only mu-
tations in the PEX12 segment of this plasmid. The myc-
tagged version of PEX12/c.26,27D cDNA was generated
by recombining the 5′ end of this cDNA with the 3′ end
of the PEX12myc cDNA. The PEX12/1-93D cDNA was
created by transferring the 1,357-bp-long BglII-XhoI
fragment from pcDNA3-PEX12 into the BamHI and
XhoI restriction-enzyme sites of pcDNA3, deleting the
first 66 codons of the PEX12 ORF and all of the 5′ UTR
of the PEX12 cDNA, and leaving M94 as the first in-
frame ATG codon. The myc-tagged version of the
PEX12/1-93D cDNA was created by removing the
1,747-bp SmaI fragment of pcDNA3-PEX12/1-93D and
replacing it with the analogous SmaI fragment of
pcDNA3-PEX12myc. Additional expression vectors de-
signed to express PEX12 cDNA products of other mu-
tant alleles were generated in a manner analogous to
that for pcDNA3-PEX12/c.26,27D. For 5′-RACE am-
plification of the PEX12 cDNA 5′ end, Marathon-Ready
cDNA (Clontech) was used as the template, together
with anchor primers supplied by the manufacturer and
two PEX12 gene–specific primers (5′-TTTGGGAGAC-
CAGCACTAGC-3′ [PEX12 RACE-3′] and 5′-TCA-
GCCATAGTTTCCTGCGTG-3′). After two rounds of
amplification, a distinct band was detected, subcloned,
and sequenced. The 5′ UTR was amplified from PEX12
cDNA and from genomic DNAs, by use of the oligonu-
cleotides Chang-120 and PEX12 RACE-3′. The PEX12
cDNA and genomic DNA sequences in GenBank (ac-
cession numbers U91521 and U91522) have been mod-
ified to reflect this new information.
Transfections, Indirect Immunofluorescence,
Antibodies, and Fluorescence Microscopy
Transfections were performed by electroporation
(Chang et al. 1997). Cells were grown to 90% con-
fluency in a 75-cm2 flask, washed twice with 10 ml of
HBS solution (21 mM HEPES, 137 mM NaCl, 5 mM
KCl, 0.7 mM Na2HPO4, and 6 mM dextrose), resus-
pended in 0.5 ml HBS, and transferred to a 0.4-cm-gap
sterile electroporation cuvette containing 10 mg DNA.
After gentle mixing of the DNA and cell suspension,
electroporation was performed in a BTX ECM600 elec-
troporator (BTX) at 220–260 V, 1,500 mF, 129 ohms.
After electroporation, cells were resuspended in 1 ml of
complete medium, transferred to a 25-cm2 flask, and
incubated at 37C. The medium was changed the next
morning, and 2 d after transfection the cells were fixed,
permeabilized, and processed for indirect immunofluo-
rescence, as described elsewhere (Slawecki et al. 1995).
Permeabilization was performed with 1% Triton X-100,
which permeabilizes both plasma and peroxisome mem-
branes. Rabbit polyclonal antibodies against the PTS1
tripeptide ser-lys-leu-COOH have been described elsewhere
(Gould et al. 1990), as has the anti–c-myc mouse mono-
clonal antibody 1-9E10 (Evan et al. 1985). Rabbit poly-
clonal antibodies against c-myc, sheep anti–human cat-
alase antibodies, and fluorescently labeled secondary
antibodies were obtained from commercial sources.
Western Blot Analysis and In Vitro Translation of
Proteins
Normal human fibroblast cells were transfected with
pcDNA3, the pcDNA3-PEX12myc gene, and the
pcDNA3-PEX12myc/c.26,27D gene. Two days after
transfection, cell lysates were prepared from each of the
three transfected cell populations by scraping the cells
into lysis buffer (10 mM Tris, pH 7.8, 1% NP40, 0.15
M NaCl, 1 mM phenylmethylsulfonyl fluoride, and 1
mM EDTA), homogenizing the lysates, and subsequently
spinning the lysates at 8,000 g, at 4C for 5 min to
remove the nuclei and cell debris. Proteins in the lysates
were separated by SDS-PAGE, transferred to Immobi-
lon-P transfer membrane (Millipore), probed with poly-
clonal anti–c-myc antibodies, and visualized by ECL
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(Amersham Life Science), according to the manufac-
turer’s protocol. PEX12 proteins were synthesized in the
presence of [35S]-methionine, by use of the TNT lysate
system (Promega), and were separated by SDS-PAGE.
The gels were fixed, incubated in sodium salicylate,
dried, and detected by fluorographic exposure of x-ray
film. Coupled in vitro transcription and translation of
PEX12 proteins from pcDNA3-based plasmids were
possible because pcDNA3 carries a T7 promoter be-
tween the cytomegalovirus promoter and the PEX12
cDNAs.
Results
Protein Import Phenotypes of PBD CG3 Cells
Our pool of PBD patients belonging to CG3 included
five individuals who were diagnosed with ZS (PBD006,
PBD040, PBD096, PBD097, and PBD098), one who was
diagnosed with NALD (PBD095), and one who dis-
played the phenotypes of IRD (PBD099). As a first step
toward defining the phenotype-genotype relationships in
these cells, we examined the import of PTS1- and PTS2-
containing proteins in skin fibroblasts that were derived
from these seven CG3 patients. Import of PTS1-con-
taining proteins was assayed by indirect immunofluo-
rescence using anti-SKL antibodies, which recognize
multiple PTS1-containing proteins (Gould et al. 1990).
To assay PTS2-protein import, skin fibroblasts from each
patient were transfected with a plasmid designed to ex-
press PAHXmyc, a C-terminally tagged version of the
PTS2 protein PAHX (Mihalik et al. 1997). Two days
after transfection, the cells were processed for indirect
immunofluorescence, by use of anti-myc antibodies. We
were unable to detect import of either PTS1 or PTS2
proteins in any of the cell lines derived from the five ZS
patients (fig. 1C and D). However, cells from the NALD
patient (PBD095) showed slight import of both PTS1-
and PTS2-containing proteins (fig. 1E and F), and cells
from the IRD patient (PBD099) exhibited even great-
er import of both classes of matrix proteins (fig. 1G
and H).
PEX12 Mutations in CG3 Patients
The simplest model of phenotype-genotype relation-
ships in the PBDs predicts that CG3 cell lines with milder
defects in peroxisomal protein import would express
some PEX12 activity. To test this hypothesis, we first
performed northern blot analysis on cells from all seven
CG3 patients. The NALD and IRD lines, PBD095 and
PBD099, had normal or nearly normal levels of PEX12
mRNA, as did the ZS lines PBD040 and PBD097. How-
ever, the ZS lines PBD006, PBD096, and PBD098 con-
tained reduced quantities of PEX12 mRNA (fig. 2),
which is a common consequence of nonsense and frame-
shift mutations (Maquat 1995).
We next determined the PEX12-gene sequence in the
CG3 patients. The 1,077-bp ORF of PEX12 is split by
just two introns, of 305 and 857 bp. A 2.3-kb fragment
of the PEX12 gene, a fragment that includes all PEX12
coding regions and short stretches of the 5′ and 3′ UTRs,
was amplified from genomic DNA by PCR and was se-
quenced directly (fig. 3A–C). Mutations were also con-
firmed independently by ASO hybridization analysis of
amplified genomic DNA (fig. 3D). In addition, all
PEX12 alleles were subcloned. Sequence analysis re-
vealed that the two mutations identified in PBD006,
PBD097, PBD098, and PBD099 were present on distinct
alleles (data not shown) (Chang et al. 1997).
The five CG3 patients with the clinical diagnosis of
ZS were all completely defective in peroxisomal matrix
protein import (fig. 1). Not surprisingly, all of the mu-
tations identified in these patients are expected to have
a severe effect on gene function. PBD006 is a compound
heterozygote for a GrT transversion at the splice-donor
site of intron 1 and a CrT transition at nucleotide 538
of the ORF (fig. 3 and table 1), both of which appear
to affect mRNA stability (of the CG3 patients whom we
examined, PBD006 had the lowest PEX12 mRNA lev-
els). The first of these mutations would block removal
of intron 1, leading to synthesis of only the first 42 amino
acids of the protein and termination after incorporation
of two additional amino acids. The second allele,
R180ter, results in premature termination at the arginine
180 codon. PBD096, who also exhibited reducedPEX12
mRNA levels, is homozygous for a 4-bp deletion
(AAGA) of nucleotides 268–271 of the ORF, which
shifts the reading frame. Its product is predicted to in-
clude the first 89 amino acids of PEX12 and to then
terminate after the addition of two extra amino acids.
PBD098 is a compound heterozygote for both a non-
sense mutation, R180ter (the same as that in PBD006),
and a 2-bp deletion of nucleotides 887–888 of the ORF,
which changes the reading frame and leads to expression
of just the first 296 amino acids, followed by addition
of 11 extra amino acids before termination. As described
in our previous report, ZS patient PBD040 is homozy-
gous for a 4-bp deletion of nucleotides 684–687 of the
ORF, truncating the protein at amino acid 228. ZS pa-
tient PBD097 is a compound heterozygote for a 4-bp
insertion at nucleotide 733 (frameshift after amino acid
244 and termination after an additional 18 residues) and
a 1-bp insertion at nucleotide 744 (frameshift after
amino acid 248 and termination after an additional 14
amino acids).
We expected that, in contrast to the severe nonsense
and frameshift mutations identified in the five ZS pa-
tients from CG3, the NALD and IRD patients would
have milder mutations in PEX12. This was the case for
Figure 1 Subcellular distribution of peroxisomal proteins in PBD CG3 cell lines. The import of PTS1-containing peroxisomal proteins
was assessed by indirect immunofluorescence, by use of anti-SKL antibodies (A, C, E, and G) in human skin fibroblasts from an unaffected
individual, GM5756 (A); CG3 ZS patient PBD097 (C); the NALD patient, PBD095 (E); and the IRD patient, PBD099 (G). To assess the import
of PTS2-containing proteins, we introduced the PAHXmyc expression vector into these same cell lines (PAHX encodes the PTS2-targeted
peroxisomal enzyme PAHX, and PAHXmyc is targeted to peroxisomes by the PTS2 import pathway; Mihalik et al. 1997). The GM5756 cell
expressing PAHXmyc imports the protein into peroxisomes (B), whereas no import is detected in ZS cell line PBD097 (D). A small amount of
PTS2-protein import is detected in the NALD cell line, PBD095 (F), and even more import appears to occur in PBD099 cells (H). (Scale bar 
20 mm)
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Figure 2 PEX12 and actin mRNA levels in CG3 fibroblast cells.
Total RNA was isolated from skin fibroblast-cell lines and was sub-
jected to northern blot analysis using PEX12 cDNA as probe. Lane
1, PBD006. Lane 2, PBD040. Lane 3, PBD095. Lane 4, PBD096. Lane
5, PBD097. Lane 6, PBD098. Lane 7, PBD099. Lane 8, GM5756
(unaffected individual). Lane 9, GM8333 (unaffected individual). The
autoradiogram obtained after probing the northern blot with the
PEX12 cDNA probe is shown in the upper panel, and the size expected
for the PEX12 mRNA is noted on the right. The lower panel shows
the level of b-actin mRNA. Quantization of PEX12mRNA abundance
in each sample was performed by use of a Fuji phosphorimager.
the NALD patient, PBD095, who was homozygous for
a 3-bp deletion that removed the Leu 68 codon (L68D)
(fig. 3 and table 1). We found that expression of the
L68D cDNA partially restored peroxisomal matrix pro-
tein import in cells from the severely affected ZS patient,
PBD097, a result that is consistent with the hypothesis
that this mutation does not completely eliminate PEX12
function (data not shown). In contrast, we found that
the most mildly affected patient, PBD099, was a com-
pound heterozygote for two seemingly severe mutations:
a mutation of the intron 1 splice-donor site (GTrTT,
the same mutation as was seen in PBD006) and a 2-bp
deletion, in exon 1, that would be expected to encode
a truncated protein containing only the first eight amino
acids of PEX12, followed by six additional amino acids
(fig. 3 and table 1).
Characterization of PEX12 mRNA in PBD099
Because the mutations in PBD099 were inconsistent
with the prevailing assumptions about phenotype-ge-
notype relationships within the PBDs, we examined fur-
ther the consequences of the PEX12 mutations identified
in PBD099. Of the two PEX12 mutations in PBD099,
the intron 1 splice donor–site mutation (GTrTT) is also
present in PBD006, a severely affected ZS patient with
no peroxisomal matrix protein import and very low lev-
els of PEX12 mRNA. This result alone indicated that
the mild phenotypes of PBD099 arose from the second
PEX12 allele of PBD099 (c.26,27D). RT-PCR analysis
supported the hypothesis that the c.26,27D allele ex-
pressed the predominant form of PEX12 in PBD099
cells: PEX12 cDNA was amplified from the RNA of
PBD099, and direct sequence analysis revealed that it
all had the c.26,27D mutation (fig. 4A). Furthermore,
all of the PEX12 cDNA amplified from the RNA of
PBD099 appeared to be processed correctly (within the
sensitivity limits of RT-PCR, direct sequence analysis,
and agarose-gel electrophoresis), which indicates that
the c.26,27D mutation did not induce aberrant pro-
cessing of the PEX12 transcript. Northern blot analysis
also suggested normal PEX12 mRNA size and abun-
dance in PBD099 cells (fig. 2).
These data indicated that the c.26,27D mutation was
incorporated into a significant majority, if not all, of the
PEX12 mRNA present in the PBD099 cells. However,
it was also possible that the PEX12 cDNA that we gen-
erated by RT-PCR did not reflect all of the PEX12
mRNA in PBD099 cells. Our previous study of PEX12-
gene structure had indicated that PEX12 consists of just
three exons, but we had not identified the 5′ end of the
PEX12 mRNA, which leaves open the possibility that
additional exons exist in the 5′ region of the cDNA.
Given that exon skipping can be induced by mutations
such as those present on either of the PEX12 alleles from
PBD099 (Dietz et al. 1993), the presence of additional
exons in the 5′ region would make it possible to bypass
the c.26,27D mutation, by skipping the affected exon.
Such PEX12 mRNAs might also lack the 5′ oligonu-
cleotide used for generating the PEX12 cDNA by RT-
PCR and would not be represented in PEX12 cDNA
from PBD099. Therefore, it was necessary to determine
the 5′ end of the PEX12 mRNA and to complete the
analysis of PEX12-gene structure.
Using 5′ RACE, we obtained cDNA clones that ex-
tended the 5′ end of the PEX12 cDNA an additional
519 bp upstream of the PEX12 ORF, yielding a 5′ UTR
of 537 bp (fig. 4B). Multiple 5′-RACE clones were iden-
tified, and all were approximately the same length. To
determine whether any introns might spilt the 5′ UTR
of PEX12 into separate exons, we amplified the 5′ UTR
of PEX12 from control human cDNA and genomic
DNA samples (fig. 4C). The presence of similarly sized
products in both reactions demonstrated that the 5′ UTR
of PEX12 cDNA is colinear with the PEX12 gene. The
absence of any upstream introns allowed us to conclude
that the 5′ oligonucleotide used for RT-PCR amplifica-
tion of PEX12 cDNA lies within exon 1 of the gene, as
shown in figure 4D. Nevertheless, we again performed
RT-PCR analysis of PEX12 mRNA from PBD099 cells
and from a control cell line from an unaffected individ-
ual, this time using a 5′ primer located near the 5′ end
of the PEX12 mRNA. Identically sized products were
obtained from both reactions. Once again, all of the
longer PEX12 cDNA from PBD099 cells has the
c.26,27D mutation but otherwise normal PEX12 struc-
ture (data not shown).
Figure 3 PEX12 mutations in CG3 PBD patients. A 2.3-kb genomic DNA fragment spanning the PEX12 gene was amplified from each
of five CG3 patients and a control and either was sequenced directly or was subjected to ASO analysis. All PBD mutations are shown here,
some by direct sequencing and others by ASO. A, Comparison of PEX12 sequence over nucleotides 527–545 of the ORF from a control
individual (top), PBD006 (middle), and PBD098 (bottom). Note that PBD006 and PBD098 are heterozygous for the CGArTGA, R180ter
mutation. B, PEX12 sequence at the splice-donor site of intron 1 from a control individual (top), PBD006 (middle), and PBD099 (bottom).
Intronic sequences are shown as lowercase letters. C, PEX12 sequence over nucleotides 885–907 of the PEX12 ORF from a control individual
(top) and PBD098 (bottom), who is heterozygous for a 2-bp deletion (TC). The resulting differences are underlined. D, ASO-hybridization
analysis of PEX12 mutations. Each panel shows autoradiograms of slot blots in which the PEX12 gene from control and PBD CG3 patients
was hybridized with radiolabeled oligonucleotides. Each panel represents two filters, with the control DNA on the left and with the patient
DNA on the right (filters Ia and Ib, PBD095 genomic DNA; filters IIa and IIb, PBD096 genomic DNA; filters IIIa and IIIb, PBD099 genomic
DNA). In each panel, the upper filter (a) was hybridized with the control oligonucleotide, and the lower filter (b) was hybridized with the
mutant oligonucleotide. Note that PBD006, PBD098, and PBD099 are compound heterozygotes, whereas PBD095 and PBD096 are homozygous
for their mutations.
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Table 1
Summary of Clinical Phenotypes, Peroxisome Protein Import Properties, and PEX12 Gene Structures of PBD CG3 Patients
Cell Line
Clinical
Phenotype
Life
Span
PTS1-Protein
Import
PTS2-Protein
Import
PEX12
mRNA
Level
(%) Mutation(s)
Predicted
Consequence
of Mutation
PBD006 ZS 3 mo   14 GTrTT at splice donor site
of intron 1
Aberrant splicing
538CrT R180ter
PBD040 ZS 3 mo   92 684–687delTAGT Frameshift
PBD095 NALD 14 years   48 202–204delCTT L68D
PBD096 ZS Unknown   34 268–271delAAGA Frameshift
PBD097 ZS 1 mo   60 733–734insGCCT
744–745insT
Frameshift
PBD098 ZS 1 mo   29 538CrT R180ter
887–888delTC Frameshift
PBD099 IRD 123 years   70 26–27delCA Frameshift
GTrTT at splice-donor site
of intron 1
Aberrant splicing
GM5756 Unaffected   100
Activity of the PEX12/c.26,27D cDNA
The fact that the c.26,27D mRNA was the predomi-
nant PEX12 mRNA present in PBD099 cells indicated
that it was responsible for the mild phenotypes of this
patient. This hypothesis was tested directly by means of
the PEX12 functional complementation assay (Chang
et al. 1997). A PEX12-deficient cell line, PBD097 (table
1), was transfected with vectors designed to express C-
terminally myc-tagged derivatives of the wild-type and
c.26,27D PEX12 cDNAs (we have demonstrated pre-
viously that addition of the myc tag to the C-terminus
of PEX12 does not affect its activity; Chang et al. 1997).
After 2 d of incubation, the transfected cell populations
were processed for indirect immunofluorescence and
were examined to determine the percentage of cells im-
porting peroxisomal matrix proteins and expressing
PEX12myc. These data revealed that the PEX12myc/
c.26,27D cDNA displayed significant PEX12 activity
that was that of the wild-type expression vector1∼ 7
(table 2). This level of activity is similar to that reported
for a mild allele of PEX1 that also results in the IRD
phenotype (Reuber et al. 1997). Thus, the sole PEX12
mRNA detected in PBD099 cells displays a level of
PEX12 activity that is consistent with the phenotypes
of PBD099.
Products of the PBD099 c.26,27D Allele
The deduced product of the PEX12/c.26,27D mRNA
consists of the first eight amino acids of the protein, a
short peptide that is extremely unlikely to mediate
PEX12 function. Therefore, we used an in vitro trans-
lation system to test the hypothesis that alternative
PEX12 proteins might be produced from the PEX12/
c.26,27D mRNA. Rabbit reticulocyte lysates containing
[35S]-methionine were charged with transcripts from the
wild-type and c.26,27D PEX12 cDNAs as well as with
those from a truncated PEX12 cDNA in which the first
in-frame AUG corresponds to the codon for M94
(PEX12/1-93D). The PEX12 ORF has several internal
AUG codons (at nucleotides 30, 94, 118, 168, 220, 221,
and 300), but the M94 AUG codon has the correct se-
quence context (i.e., gua.AUG.g) for high-efficiency
translation initiation (Kozak 1992). The products of
these in vitro translation reactions were then analyzed
after separation by SDS-PAGE. The deduced molecular
mass of PEX12 is 39 kD, and the wild-type PEX12
cDNA directed the synthesis of an ∼40-kD protein (fig.
5A). However, the product of the PEX12/c.26,27D
cDNA was ∼29 kD, the size expected for a protein in-
itiating at the M94 codon. The product of the PEX12/
1-93D cDNA was also 29 kD (fig. 5A, lane 3).
The 29-kD product of the PEX12/c.26,27D mRNA
could be generated only by translation initiation at an
internal AUG codon. To test whether similarly sized pro-
teins were generated from the c.26,27D allele, we utilized
a gene-transfection assay (we have demonstrated else-
where that the PEX12 gene, complete with all intronic
sequences, rescues the defects of PEX12-deficient cells
as efficiently as does the PEX12 cDNA; Chang et al.
1997). Human fibroblasts were transfected with plas-
mids designed to express C-terminally myc-tagged ver-
sions of the wild-type and c.26,27D PEX12 genes. Two
days after transfection, the products of each gene were
detected by western blot analysis using anti-myc anti-
bodies. Cells transfected with the PEX12myc gene con-
tained full-length PEX12myc of the predicted size,
∼40 kD (fig. 5B; the myc tag adds ∼1 kD to the size of
Figure 4 PEX12 structure in normal and PBD099 cells. A, Direct sequence analysis of PBD099 cDNA. PEX12 RNA from control cells
and from PBD099 cells was converted to cDNA by RT-PCR using oligonucleotides flanking the PEX12 ORF. Direct sequence analysis of the
control PEX12 cDNA (top) and PBD099 PEX12 cDNA (bottom) revealed that all cDNA from PBD099 cells had the 2-bp deletion from the
c.26,27D allele (conversion of CACA to CA). B, Sequence of PEX12 exon 1, as deduced from 5′-RACE and genomic DNA analysis. The in-
frame stop codon upstream of the PEX12 ORF is overlined, and the underlined sequences correspond to the oligonucleotides used in panel C.
C, Agarose-gel electrophoresis analysis of 5′-UTR amplification products. The products were generated with either cDNA (lane 1) or genomic
DNA (lane 2) used as the template and with the oligonucleotides underlined in panel B used as primers. D, Diagram of transcribed segment
of the PEX12 gene. Blocks represent exonic sequences, and intervening lines represent the two PEX12 introns. Blackened segments represent
coding regions of the exons, whereas unblackened segments represent the 5′ UTR and 3′ UTR. Oligonucleotides used for amplification of the
PEX12 gene and cDNA fragments are represented as lines shown above and below the gene diagram. Oligonucleotides a and b (Chang-21 and
Chang-20, respectively) were used for RT-PCR amplification of PEX12 cDNA, as described in panel A; oligonucleotides d and c (Chang-120
and PEX12 RACE-3′, respectively) were used for amplification of the PEX12 5′ UTR from both genomic DNA and cDNA, as described in
panel C; oligonucleotides d and b were used for RT-PCR amplification of the 5′-UTR and ORF, as described in the text.
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Table 2
In Vivo PEX12 Activities Expressed by Wild-Type and c.26,27D
PEX12myc
PEX12myc
Type
Expressiona
(%)
Activityb
(%)
Normalized
Activityc
Relative
Rescue
Activityd
(%)
Wild type 9.79 49.45 5.05 100
26,27D 3.12 2.62 .84 16.63
a Proportion of myc-positive cells, among 1,500.
b Proportion of cells exhibiting catalase import, among 1,500.
c Calculated by dividing “Activity” by “Expression.”
d Normalized activity as percentage of wild-type activity.
PEX12). In contrast, cells transfected with the
PEX12myc/c.26,27D gene contained two shorter PEX12
proteins, ∼30 and ∼27 kD in size, the smaller of which
was also synthesized from the wild-type gene; these pro-
teins have the intact PEX12 C-terminus (the myc tag is
located at this position) and have the size expected for
proteins that initiate at the M94 and M118 AUG co-
dons, respectively.
Discussion
The pioneering cell-fusion complementation studies of
Brul et al. (1988) and Roscher et al. (1989) established
that ZS, NALD, and IRD are genetically heterogeneous
and that all three classes of patients could be found
within a single CG. The simplest interpretation of these
data is that the differences between ZS, NALD, and IRD
patients are caused by differences in allele severity. Al-
though the limited mutation studies reported in the in-
itial characterizations of the PEX2 (Shimozawa et al.
1992), PEX6(Fukuda et al. 1996; Yahraus et al. 1996),
PEX12(Chang et al. 1997; Okumoto and Fujiki 1997),
PEX7(Braverman et al. 1997; Motley et al. 1997; Pur-
due et al. 1997), PEX1(Portsteffen et al. 1997; Reuber
et al. 1997), and PEX10 (Warren et al. 1998) genes have
provided anecdotal support to this hypothesis, there has
yet to be a systematic analysis of phenotype-genotype
correlations within any group of PBD patients.
In the present report, we have shown that both alleles
of PEX12 are mutated in all seven representatives of
CG3 in our patient population, which confirms the ear-
lier observation that mutations in PEX12 are responsible
for disease in CG3 of the PBD (Chang et al. 1997; Oku-
moto and Fujiki 1997). In CG3, the five ZS patients
have the most pronounced clinical deficits, lack detect-
able matrix protein import, and have nonsense, frame-
shift, or splice-site mutations on both alleles of PEX12.
The hypothesis that milder mutations in PEX12 would
result in less pronounced cellular and clinical phenotypes
was supported by our analysis of PBD095. This NALD
patient has relatively mild clinical phenotypes, including
an extended life span (currently 4 years), and imports
detectable amounts of PTS1 and PTS2 proteins. This
individual is homozygous for an in-frame deletion of one
codon, L68, which reduced but did not eliminatePEX12
activity. However, PBD099 presented a paradox.
PBD099 displayed the mildest clinical and cellular phe-
notypes of all CG3 patients but was a compound het-
erozygote for the following mutations, which would
truncate the protein shortly after initiation: (1) a splice
donor–site mutation in intron 1 and (2) a 2-bp frame-
shifting mutation in codon 9 of the PEX12 ORF. The
first of these mutations is also present in a ZS patient
(PBD006) who contains little PEX12 mRNA and dis-
plays a severe defect in peroxisomal matrix protein im-
port. This result alone implicated the second PBD099
PEX12 allele in the expression of detectable PEX12 ac-
tivity. This hypothesis was supported by two other ob-
servations. First, the only PEX12 mRNA detected in
PBD099 cells carried the c.26,27D mutation, and, sec-
ond, the PEX12/c.26,27D cDNA had significant PEX12
activity, that of the wild-type cDNA. A similar de-1∼ 7
crease in PEX-gene activity is associated with the PEX1/
G843D allele, a mutation that also results in IRD phe-
notypes (Reuber et al. 1997).
These data clearly implicate the PEX12/c.26,27D al-
lele as the source of PEX12 activity in PBD099. How-
ever, they do not explain how significant PEX12 activity
was generated from an mRNA that is predicted to en-
code just the first eight amino acids of PEX12, partic-
ularly in light of mutation data from other PEX12-
deficient patients demonstrating that other regions of
PEX12 are critical for function. Therefore, we charac-
terized further the protein products of the c.26,27D
mRNA. In vitro translation studies demonstrated that
the PEX12/c.26,27D mRNA directed the synthesis of a
29-kD protein, a product that could only be synthesized
by translation initiation at an internal AUG codon. A
protein of identical size was synthesized from a truncated
PEX12 mRNA in which M94 was the first in-frame start
codon. Furthermore, the M94 codon is in the correct
context (i.e., gua.AUG.g) for high-efficiency translation
initiation. Gene-transfection studies also indicated that
the c.26,27D allele could direct the synthesis of N-ter-
minally truncated PEX12 proteins, adding further sup-
port to the hypothesis that PEX12 activity may be gen-
erated by translation initiation at internal AUG codons
along the PEX12/c.26,27D mRNA. However, it should
be noted that we did not sequence the PEX12 protein(s)
present in PBD099 cells. Therefore, it is formally pos-
sible that the truncated PEX12 proteins observed in the
in vitro translation and in gene-transfection studies may
have been generated by some unknown mechanism.
If it can be assumed that translation at one or more
internal AUG codons is responsible for the synthesis of
truncated PEX12 proteins from the c.26,27D allele, how
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Figure 5 PEX12 products of the c.26,27D allele. The positions
of molecular-weight markers are shown to the left of both panels. A,
SDS-PAGE mobilities of in vitro–synthesized PEX12 proteins. Rabbit
reticulocyte lysates were used to synthesize [35S]-labeled products of
PEX12 cDNA (lane 2), PEX12/c.26,27D cDNA (lane 3), and PEX12/
1-93D cDNA (lane 4). Equivalent portions of each sample were then
separated by SDS-PAGE, and radiolabeled proteins were detected by
fluorography. Lane 1 contained an equivalent amount of rabbit retic-
ulocyte lysate. Arrows indicate the mobilities of the full-length PEX12
protein (upper arrow) and the product of the c.26,27D and 1-93D
cDNAs (lower arrow). B, Proteins produced from the PEX12myc and
PEX12myc/c.26,27D genes. Normal human skin fibroblasts were
transfected with vector alone (lane 1) and with plasmids designed to
express either the PEX12myc gene (lane 2) or the PEX12myc/c.26,27D
gene (lane 3). Two days after transfection, cell lysates were prepared,
separated by SDS-PAGE, and subjected to immunoblot analysis using
polyclonal anti-myc antibodies. The two lowermost arrows to the right
of the blot show the mobilities of myc-tagged proteins expressed from
the PEX12myc/c.26,27D gene. The topmost arrow indicates the ob-
served mobility of full-length PEX12myc. Note that the lower band
produced from the PEX12myc/c.26,27D gene was also produced from
the wild-type PEX12myc gene. All samples also had a reactive band
of ∼47 kD, which may be derived from the endogenous c-myc protein.
might this occur? Internal ribosome-entry sites have been
identified in certain mammalian mRNAs, allowing trans-
lation at downstream AUGs. Such an element may pre-
cede M94 in the PEX12 mRNA. However, it is also
possible that truncated PEX12 proteins may be ex-
pressed through a termination/reinitiation mechanism
such as that which occurs in certain viral and artificial
polycistronic mRNAs of mammalian cells (Peabody and
Berg 1986). In mammalian cells, expression by termi-
nation/reinitiation on polycistronic mRNAs is inefficient
and can be greatly influenced by the relative position of
the upstream and downstream ORFs of the mRNA (Pea-
body et al. 1986). It is interesting to note that a ZS
patient (PBD096) who is homozygous for a frameshift
mutation following codon 89 also has M94 as the first
AUG in the ORF. However, the mRNA produced from
the PBD096 alleles has a 4-bp deletion 8 bp upstream
of M94 and fails to express detectable PEX12 activity
in vivo. If internal ribosome entry is responsible for ex-
pression of truncated PEX12 proteins in PBD099 cells,
then the 4-bp deletion in PBD096 may disrupt the se-
quence required for internal translation initiation. Al-
ternatively, if truncated PEX12 is synthesized by ter-
mination and subsequent reinitiation, the increased size
and relative proximity of the upstream ORF in PBD096
may affect the reinitiation efficiency at either M94 or
M118 and thus affect the ability to express PEX12 func-
tion in PBD096 cells.
Translation initiation at internal AUG codons is rare
but has been demonstrated for many genes. In addition
to instances in which upstream AUG codons are nor-
mally skipped in favor of downstream start sites (Kozak
1989), termination and reinitiation on viral and artificial
polycistronic mRNAs has been observed in mammalian
cells (Peabody and Berg 1986), as has internal ribosome
entry (McBratney et al. 1993; Belsham and Sonenberg
1996). Although we are unaware of any other instances
in which this mechanism is thought to modulate hu-
man disease phenotypes, translation initiation at internal
AUG codons along the murine androgen-receptor
mRNA has been invoked to explain the relatively mild
phenotypes of the Tfm mouse, a mutant caused by a
nonsense mutation farther 5′ in the androgen-receptor
gene (Gaspar et al. 1991). In view of our results with
PEX12 in PBD099, it may be that internal translation
initiation should be considered when one is faced with
the paradox of mild phenotypes and apparently severe
mutations, particularly when the mutations lie early in
the coding region of the disease gene.
In summary, we find that the relationship between
genotype and phenotype in PEX12-deficient patients is
relatively straightforward. Loss-of-function alleles ap-
pear to cause both severe defects in peroxisomal matrix
protein import and severe clinical phenotypes, whereas
alleles with partial PEX12 activity lead to partial defects
in protein import and relatively mild clinical phenotypes.
The human PEX12 gene has been cloned independently,
and mutations for three PBD patients have been reported
by Fujiki and colleagues (Okumoto and Fujiki 1997;
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Okumoto et al. 1998). These include a K231ter muta-
tion in PBD3-02 (Okumoto and Fujiki 1997), an S292ter
mutation in PBD3-01, and an R180ter mutation in
PBD3-03 (Okumoto et al. 1998), all of whom are
thought, on the basis of analysis of RT-PCR-generated
cDNAs from these patients, to be homozygotes. Inter-
estingly, PBD3-03 is the same as patient PBD006 of this
report, a compound heterozygote for the R180ter mu-
tation and the intron 1 splice donor–site mutation that
is also found in PBD099 cells. The inability of Okumoto
et al. (1998) to detect cDNAs emanating from the allele
with the intron 1 splice donor–site mutation lends in-
dependent support to the hypothesis that this allele can-
not be expressed and thus that the c.26,27D allele is
indeed the predominant form of PEX12 expressed in
PBD099 cells. Although we used different techniques for
genotype and phenotype analysis than were used by Fu-
jiki and colleagues, the fact that the latter group iden-
tified nonsense mutations (K231ter and S292ter) in ZS
patients lends support to the hypothesis that severe mu-
tations in PEX12 lead to severe clinical phenotypes.
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